<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210419051016N3</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-06-17</date_registration>
      <primary_sponsor>Esfahan University of Medical Sciences</primary_sponsor>
      <public_title>Comparative Evaluation of the effect of tranexamic acid impregnated gauze with gelatamp in controlling bleeding</public_title>
      <acronym></acronym>
      <scientific_title>Comparative Evaluation of the effect of tranexamic acid impregnated gauze with gelatamp in controlling bleeding after the extraction of four maxillary primary incisors in children candidates for dental treatment under general anesthesia</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-04-16</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>30</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/69399</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Crossover, Purpose: Treatment, Randomization description: Children who are candidates for extraction of primary teeth who refer to the hospital dental department of Isfahan Faculty of Dentistry during the study, if they are eligible, will be included in the study and will be randomly assigned by
 simple randomization method and individually with the help of a table of 
random numbers; In this method, the 'AB' order is considered for each odd number, and the 'BA' order is considered for each even number. Then a column is randomly selected from the table and if the first selected number is odd, the 'AB' order is applied which means the first patient is allocated in the A group and receives GELATAMP treatment, and as a result, the next patient is allocated to the B group and receives TRANEXAMIC ACID IMPREGNATED GAUZE treatment. Similarly, If the selected number is even, the 'BA' order is applied and the first patient is allocated in the B group and receives TRANEXAMIC ACID IMPREGNATED GAUZE  treatment, and as a result, the next patient is allocated to the A group and receives GELATAMP treatment.
This is repeated 15 times until you get 15 samples in each group, Blinding description: Outcome assessor was not aware of the type of material used for each tooth while evaluating the treated teeth clinically and radiographically.
This study will be conducted in a double-blind manner so that the examining clinician and data analyst will not know the type of intervention.</study_design>
      <phase>3</phase>
      <hc_freetext>Tranexamic Acid, Controlling Bleeding, Gelatamp.</hc_freetext>
      <i_freetext>Intervention 1: The first intervention group: Gelatamp, after extraction for two teeth, two pieces of Gelatamp (Spongostan, Ferrosan, Denmark) will be placed half inside the socket and after a period of 4 weeks in the second phase of the  study, the groups will be changed. Intervention 2: The second intervention group: Tranexamic acid impregnated gauze, a gauze with dimensions of 2 x 2, impregnated with 4cc of ampoule of tranexamic acid (Tranexip, Caspian Tamin, Iran) with a dose of 500 mg/5  ml will be applied to two similar teeth and after a period of 4 weeks in the  second phase of the study, the groups will be changed.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Maryam Hajiahmadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Pediatric Dentistry department, Faculty of Dentistry, Isfahan University of Medical Sciences, Hezar jerib St.</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>81746-73461</zip>
        <telephone>+98 31 3792 5539</telephone>
        <email>dr.maryamhajiahmadi@gmail.com</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Maryam Hajiahmadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>School of Dentistry, Isfahan University of Medical Sciences, Hezar Jerib St., Isfahan</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۸۱۷۴۶-۷۳۴۶۱</zip>
        <telephone>+98 31 3792 5539</telephone>
        <email>dr.maryamhajiahmadi@gmail.com</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>The need to Extract Primary incisors
Age 2 to 4 years
Children are not affected to Congenital Hemorrhagic Diseases
Children should not receive Anticoagulants
The Child does not have a Mental or Physical Disability
The Studied Teeth should have less than One-third root Resorption and unmaintainable Crowns
Do not take Ibuprofen and Aspirin Painkillers before and after work
The Child does not have Contraindications for General Anesthesia
The Studied Child only needs to have four Primary incisors Extracted and another Tooth Extracted from the Patient
If the Tooth is not Infected and the root has not Decayed to a large extent, it is included in the Study
If They do not have Complications during General Anesthesia. (Hypoxia, Blood Pressure drop, Larynx Spasm, etc.)</inclusion_criteria>
      <agemin>2 years</agemin>
      <agemax>4 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>History of any uncontrolled systemic disease
Patients whose parents do not consent to participate in the study for any reason</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>The first intervention group: Gelatamp, after extraction for two teeth, two pieces of Gelatamp (Spongostan, Ferrosan, Denmark) will be placed half inside the socket and after a period of 4 weeks in the second phase of the  study, the groups will be changed.</i_keyword>
      <i_keyword>The second intervention group: Tranexamic acid impregnated gauze, a gauze with dimensions of 2 x 2, impregnated with 4cc of ampoule of tranexamic acid (Tranexip, Caspian Tamin, Iran) with a dose of 500 mg/5  ml will be applied to two similar teeth and after a period of 4 weeks in the  second phase of the study, the groups will be changed.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Intensity of Bleeding. Timepoint: The determined time intervals are 10, 5, and 15 minutes after starting to use Gelatamp and gauze impregnated with Tranexamic acid. Method of measurement: Fanning scale.</prim_outcome>
      <prim_outcome>Bleeding Time. Timepoint: The determined time intervals are 10, 5, and 15 minutes after starting to use Gelatamp and gauze impregnated with Tranexamic acid. Method of measurement: Fanning scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Oral Health. Timepoint: At the beginning of the study (before the start of the intervention) and Two weeks after the end of the intervention. Method of measurement: Examination of the child's mouth.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Esfahan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-03-18</approval_date>
        <contact_name>Ethics committee of Isfahan University of Medical Sciences</contact_name>
        <contact_address>Ground Floor, Faculty of Medicine, Building No. 3, Isfahan University of Medical Sciences,Hezar Jerib St., Isfahan   , Phone number: 03137923080 Isfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
